Recipient, transplant, and donor characteristics
| Patient characteristics . | Fresh . | Cryopreserved . | P . |
|---|---|---|---|
| Patients, n | 203 | 101 | |
| Age, y, median (range) | 65 (21, 78) | 63 (25, 77) | .2 |
| Sex, n (%) | .9 | ||
| Male | 121 (59.6) | 59 (58.4) | |
| Female | 82 (40.4) | 42 (41.6) | |
| Diagnosis, n (%) | .98 | ||
| ALL | 23 (11.3) | 12 (11.9) | |
| AML | 80 (39.4) | 38 (37.6) | |
| Atypical leukemia | 1 (0.5) | 0 (0) | |
| CLL | 2 (1) | 1 (1) | |
| CML | 1 (0.5) | 2 (2) | |
| HLH | 2 (1) | 2 (2) | |
| MDS | 41 (20.2) | 17 (16.8) | |
| MDS/MPN | 2 (1) | 1 (1) | |
| MPAL | 1 (0.5) | 0 (0) | |
| MPN | 29 (14.3) | 16 (15.8) | |
| NHL | 17 (8.4) | 10 (9.9) | |
| T-PLL | 4 (2) | 2 (2) | |
| Disease status at transplant, n (%) | .59 | ||
| Complete response | 118 (58.2) | 63 (62.4) | |
| Partial response | 15 (7.4) | 6 (5.9) | |
| Stable disease | 42 (20.7) | 24 (23.8) | |
| Progressive disease | 2 (1) | 2 (2) | |
| Induction failure | 18 (8.9) | 4 (4) | |
| Untreated | 6 (3) | 2 (2) | |
| NA | 2 (1) | 0 (0) | |
| Recipient/donor CMV serological status, n (%) | .3 | ||
| R−/D− | 71 (35) | 39 (38.6) | |
| R−/D+ | 52 (25.6) | 17 (16.8) | |
| R+/D− | 47 (23.2) | 25 (24.8) | |
| R+/D+ | 33 (16.3) | 19 (18.8) | |
| Unknown | 0 (0) | 1 (1) | |
| Hematopoietic cell transplantation-specific comorbidity index, n (%) | .73 | ||
| 0 to 2 | 67 (33.1) | 32 (31.8) | |
| ≥3 | 136 (67) | 69 (68.3) | |
| Median (range) | 4 (0, 10) | 4 (0, 10) | |
| DRI, n (%) | .39 | ||
| Low | 9 (4.4) | 9 (8.9) | |
| Intermediate | 113 (55.7) | 58 (57.4) | |
| High | 74 (36.5) | 31 (30.7) | |
| Very high | 7 (3.4) | 3 (3) | |
| KPS, n (%) | 1 | ||
| <90 | 108 (53.2) | 54 (53.5) | |
| 100 to 90 | 95 (46.8) | 47 (46.5) | |
| Transplant characteristics | |||
| Conditioning intensity, n (%) | .08 | ||
| Myeloablative (MAC) | 50 (24.6) | 35 (34.7) | |
| Reduced intensity (RIC) | 153 (75.4) | 66 (65.3) | |
| aGVHD prophylaxis regimen, n (%) | .008 | ||
| Tacrolimus/MMF/cyclophosphamide | 25 (12.3) | 23 (22.8) | |
| Tacrolimus/methotrexate | 123 (60.6) | 65 (64.4) | |
| Tacrolimus/rapamycin/methotrexate | 50 (24.6) | 13 (12.9) | |
| Tacrolimus/rapamycin | 5 (2.5) | 0 (0) | |
| Year of transplant | |||
| 2019 | 147 (72.4) | 6 (5.9) | <.05 |
| 2020 | 56 (27.6) | 95 (94.1) | |
| Donor characteristics | |||
| HLA match, n (%) | .77 | ||
| 10/10 | 170 (83.7) | 84 (83.2) | |
| <10/10 | 33 (16.3) | 17 (16.9) | |
| Donor origin, n (%) | .72 | ||
| Domestic | 106 (52.2) | 55 (54.5) | |
| International | 97 (47.8) | 46 (45.5) | |
| Donor age, y, median (range) | 28 (19, 54) | 28 (19, 64) | .09 |
| Donor sex | 1 | ||
| Male | 129 (63.5) | 65 (64.4) | |
| Female | 74 (36.5) | 36 (35.6) | |
| Male recipient/female donor, n (%) | 29 (14.3) | 19 (18.8) | .32 |
| Patient characteristics . | Fresh . | Cryopreserved . | P . |
|---|---|---|---|
| Patients, n | 203 | 101 | |
| Age, y, median (range) | 65 (21, 78) | 63 (25, 77) | .2 |
| Sex, n (%) | .9 | ||
| Male | 121 (59.6) | 59 (58.4) | |
| Female | 82 (40.4) | 42 (41.6) | |
| Diagnosis, n (%) | .98 | ||
| ALL | 23 (11.3) | 12 (11.9) | |
| AML | 80 (39.4) | 38 (37.6) | |
| Atypical leukemia | 1 (0.5) | 0 (0) | |
| CLL | 2 (1) | 1 (1) | |
| CML | 1 (0.5) | 2 (2) | |
| HLH | 2 (1) | 2 (2) | |
| MDS | 41 (20.2) | 17 (16.8) | |
| MDS/MPN | 2 (1) | 1 (1) | |
| MPAL | 1 (0.5) | 0 (0) | |
| MPN | 29 (14.3) | 16 (15.8) | |
| NHL | 17 (8.4) | 10 (9.9) | |
| T-PLL | 4 (2) | 2 (2) | |
| Disease status at transplant, n (%) | .59 | ||
| Complete response | 118 (58.2) | 63 (62.4) | |
| Partial response | 15 (7.4) | 6 (5.9) | |
| Stable disease | 42 (20.7) | 24 (23.8) | |
| Progressive disease | 2 (1) | 2 (2) | |
| Induction failure | 18 (8.9) | 4 (4) | |
| Untreated | 6 (3) | 2 (2) | |
| NA | 2 (1) | 0 (0) | |
| Recipient/donor CMV serological status, n (%) | .3 | ||
| R−/D− | 71 (35) | 39 (38.6) | |
| R−/D+ | 52 (25.6) | 17 (16.8) | |
| R+/D− | 47 (23.2) | 25 (24.8) | |
| R+/D+ | 33 (16.3) | 19 (18.8) | |
| Unknown | 0 (0) | 1 (1) | |
| Hematopoietic cell transplantation-specific comorbidity index, n (%) | .73 | ||
| 0 to 2 | 67 (33.1) | 32 (31.8) | |
| ≥3 | 136 (67) | 69 (68.3) | |
| Median (range) | 4 (0, 10) | 4 (0, 10) | |
| DRI, n (%) | .39 | ||
| Low | 9 (4.4) | 9 (8.9) | |
| Intermediate | 113 (55.7) | 58 (57.4) | |
| High | 74 (36.5) | 31 (30.7) | |
| Very high | 7 (3.4) | 3 (3) | |
| KPS, n (%) | 1 | ||
| <90 | 108 (53.2) | 54 (53.5) | |
| 100 to 90 | 95 (46.8) | 47 (46.5) | |
| Transplant characteristics | |||
| Conditioning intensity, n (%) | .08 | ||
| Myeloablative (MAC) | 50 (24.6) | 35 (34.7) | |
| Reduced intensity (RIC) | 153 (75.4) | 66 (65.3) | |
| aGVHD prophylaxis regimen, n (%) | .008 | ||
| Tacrolimus/MMF/cyclophosphamide | 25 (12.3) | 23 (22.8) | |
| Tacrolimus/methotrexate | 123 (60.6) | 65 (64.4) | |
| Tacrolimus/rapamycin/methotrexate | 50 (24.6) | 13 (12.9) | |
| Tacrolimus/rapamycin | 5 (2.5) | 0 (0) | |
| Year of transplant | |||
| 2019 | 147 (72.4) | 6 (5.9) | <.05 |
| 2020 | 56 (27.6) | 95 (94.1) | |
| Donor characteristics | |||
| HLA match, n (%) | .77 | ||
| 10/10 | 170 (83.7) | 84 (83.2) | |
| <10/10 | 33 (16.3) | 17 (16.9) | |
| Donor origin, n (%) | .72 | ||
| Domestic | 106 (52.2) | 55 (54.5) | |
| International | 97 (47.8) | 46 (45.5) | |
| Donor age, y, median (range) | 28 (19, 54) | 28 (19, 64) | .09 |
| Donor sex | 1 | ||
| Male | 129 (63.5) | 65 (64.4) | |
| Female | 74 (36.5) | 36 (35.6) | |
| Male recipient/female donor, n (%) | 29 (14.3) | 19 (18.8) | .32 |
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; HLH, hemophagocytic lymphohistiocytosis; KPS, Karnofsky performance score; MDS, myelodysplastic syndrome; MMF, mycophenolate mofetil; MPAL, mixed phenotype acute leukemia; MPN, myeloproliferative neoplasms; NHL, non-Hodgkin lymphoma; T-PLL, T-cell prolymphocytic leukemia.